<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888082</url>
  </required_header>
  <id_info>
    <org_study_id>D8664L00012</org_study_id>
    <nct_id>NCT00888082</nct_id>
  </id_info>
  <brief_title>Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy</brief_title>
  <acronym>PROOF</acronym>
  <official_title>Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients Undergoing Adjuvant Chemotherapy: An Open Label, Randomised, Multi-Centre, Phase IIIb Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this study is to determine the effectiveness of goserelin acetate
      (Zoladex) in preserving ovarian function in premenopausal women undergoing adjuvant
      chemotherapy for primary invasive breast cancer by documenting persistence or resumption of
      regular menses via menstrual history, serum FSH and E2 measurements.

      The secondary objectives of this study are as follows: To investigate the impact of treatment
      with chemotherapy with or without goserelin acetate (i.e. impact of the expectation of
      ovarian function preservation) on participants' quality of life (QOL) by FACT-ES scale, and
      to compare safety and tolerability of study drugs in two treatment groups by evaluation of
      adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ovarian function will be considered as regained, if E2 measurements return to premenopausal levels (equal to or above 20 pg/ml), FSH measurements return to premenopausal levels (less than or equal to 40 IU/L)</measure>
    <time_frame>Each 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The ovarian function will be considered as regained, if menstrual bleeding is observed in two consecutive menstrual cycles</measure>
    <time_frame>Each 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) through-out the study measured by FACT-ES scale.</measure>
    <time_frame>Each 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Function</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receiving only adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receiving goserelin acetate along with adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin acetate</intervention_name>
    <description>3.6 mg depot injectable preparation</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zoladex 3.6 mg Depot</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed invasive breast carcinoma

          -  Candidates for adjuvant chemotherapy for primary breast cancer

          -  Premenopausal, verified before chemotherapy is begun as satisfying both cyclic vaginal
             bleeding and appropriate hormone levels

        Exclusion Criteria:

          -  Previous systemic chemotherapy

          -  Pregnancy

          -  Stage IV breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mustafa Özgüroğlu, Assoc.Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University Cerrahpasa Medical Faculty, Medical Oncology Clinic, Cerrahpasa 34098, Istanbul, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeşim Eralp, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University Istanbul Medical Faculty, Oncology Institute, Medical Oncology Department, Capa 34360 Istanbul, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gül Başaran, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marmara University Medical Faculty, Medical Oncology Department, Istanbul, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kadri Altundağ, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University Medical Faculty, Medical Oncology Department, Sihhiye 06100 Ankara, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filiz Çay Şenler, Assoc.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University Medical Faculty, Medical Oncology Department, Sihhiye 06100 Ankara, Turkey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Metin Özkan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erciyes University Medical Faculty, Medical Oncology Department, 38039 Kayseri, Turkey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995 Feb;52(2):365-72.</citation>
    <PMID>7711205</PMID>
  </reference>
  <reference>
    <citation>Ataya KM, McKanna JA, Weintraub AM, Clark MR, LeMaire WJ. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res. 1985 Aug;45(8):3651-6.</citation>
    <PMID>3926307</PMID>
  </reference>
  <reference>
    <citation>Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718-29. Review.</citation>
    <PMID>8622093</PMID>
  </reference>
  <reference>
    <citation>Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr. 2005;(34):40-3.</citation>
    <PMID>15784821</PMID>
  </reference>
  <reference>
    <citation>Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990 Jun;61(6):861-5.</citation>
    <PMID>2142603</PMID>
  </reference>
  <reference>
    <citation>Brincker H, Rose C, Rank F, Mouridsen HT, Jakobsen A, Dombernowsky P, Panduro J, Andersen KW. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987 Nov;5(11):1771-8.</citation>
    <PMID>3316514</PMID>
  </reference>
  <reference>
    <citation>Cheer SM, Plosker GL, Simpson D, Wagstaff AJ. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs. 2005;65(18):2639-55. Review.</citation>
    <PMID>16392882</PMID>
  </reference>
  <reference>
    <citation>Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, Clavarezza M, Testa D, Venturini M. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol. 2006 Jan;17(1):74-8. Epub 2005 Oct 27.</citation>
    <PMID>16254024</PMID>
  </reference>
  <reference>
    <citation>Del Mastro L, Venturini M, Sertoli MR et al. Phase III adjuvan trial comparing standard versus accelerated FEC regimen in early breast cancer patients. Results from GONO-MIG1 study. Breast Cancer Res Treat 2003; 82 (Suppl 1): S9 (Abstr).</citation>
  </reference>
  <reference>
    <citation>Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997 Apr;43(2):183-90. Review.</citation>
    <PMID>9131274</PMID>
  </reference>
  <reference>
    <citation>Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 Sep 19;352(9132):930-42.</citation>
    <PMID>9752815</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>December 9, 2010</last_update_submitted>
  <last_update_submitted_qc>December 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>goserelin acetate</keyword>
  <keyword>ovarian function</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Primary invasive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

